National Pharmaceutical Pricing Authority: NPPA asks cos to ensure critical drugs are available - (The Economic Times via NewsPoints Desk)

  • India's National Pharmaceutical Pricing Authority (NPPA) is directing certain companies to ensure the availability of critical medicines, and exempting a "novel" oncology formulation from price control, reported The Economic Times.

  • The regulator asked companies including Abbott, Bayer and Sanofi to not discontinue critical medicines for malaria, leprosy and arrhythmias without prior notice to prevent shortages in the country.

  • Abbott had sought approval to discontinue the leprosy drug Hansepran, while Bayer had done the same for the malaria treatment Resochin, and Sanofi for the cardiac drug Adenocor, sources said. 

  • Fearing that a sudden discontinuation could lead to drug shortages, the NPPA has asked the companies to issue a public notice, and continue their production, import and sale for 12 months after that.

  • The agency has also exempted Sun Pharmaceutical's ready-to-use infusion bags of gemcitabine from price control, as it is helpful in administration to patients.

To read more NewsPoints articles, click here.